WinstonWınston
Back
Bioelectronics Corporation logo

Bioelectronics Corporation

BIEL
Medical - Specialties · Healthcare
Price
$0.00
+0.00 (+20.00%)
Market Cap
$7.4M
Exchange
Other OTC
Winston Score
Winston looking sleepy
No score yet — Winston is napping.
We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+1.8% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 24.26B (2021) → 24.71B (2025)

Winston Score History

The full picture

Bioelectronics Corporation is a small medical device company that makes wearable pain relief patches. These patches use a technology called pulsed electromagnetic field (PEMF) therapy to reduce pain without drugs. The company sells products under the ActiPatch brand, targeting people with chronic pain conditions like back pain and arthritis, as well as post-surgical recovery patients.

The company earns revenue by selling its disposable and reusable patches directly to consumers and through retail and online channels, primarily in the United States and the United Kingdom. Its high gross margin reflects the relatively low manufacturing cost of its devices, but a negative return on invested capital signals the business has struggled to translate that into consistent profitability. Bioelectronics operates in a crowded pain management market where it competes against both pharmaceutical options and other non-drug devices, and its main challenge is building enough consumer awareness and clinical evidence to drive broader adoption of PEMF therapy.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-56.1% YoY

YoY Growth Rate

Revenue declining

EPS Growth

<−1,000% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$128,312/ year

Declining (-52% vs prior year)

25.1% of revenue

In line with sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

69.5%ownership

Insiders own a meaningful stake in the company

Cash Runway

~0 months

$6,871 cash & investments

Short runway — potential dilution ahead through share issuance

Cash watch

Bioelectronics Corporation has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
60.7%
Premium pricing power — 60.7% gross margin
Profit after running costs
Operating Margin
-61.8%
Losing money on operations — -61.8%
Return on the money invested
ROCE
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
-63.1%
Shrinking sales (-63.1% YoY)
Profit growth
EPS YoY
N/A
Data not available
How steady the profit is
EPS Consistency
3/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
N/A
Data not available
Spare cash per sale
FCF Margin
-93.5%
Burning cash (-93.5%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
N/A
Data not available
Covers its interest
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial